Zoetis Inc. (ZTS)
NYSE: ZTS · Real-Time Price · USD
75.35
-0.85 (-1.12%)
At close: Jul 21, 2026, 4:00 PM EDT
75.47
+0.12 (0.16%)
After-hours: Jul 21, 2026, 5:23 PM EDT
Zoetis Revenue
Zoetis had revenue of $2.26B in the quarter ending March 31, 2026, with 2.91% growth. This brings the company's revenue in the last twelve months to $9.51B, up 2.64% year-over-year. In the year 2025, Zoetis had annual revenue of $9.47B with 2.28% growth.
Revenue (ttm)
$9.51B
Revenue Growth
+2.64%
P/S Ratio
3.32
Revenue / Employee
$657,310
Employees
14,500
Market Cap
31.59B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 9.47B | 211.00M | 2.28% |
| Dec 31, 2024 | 9.26B | 712.00M | 8.33% |
| Dec 31, 2023 | 8.54B | 464.00M | 5.74% |
| Dec 31, 2022 | 8.08B | 304.00M | 3.91% |
| Dec 31, 2021 | 7.78B | 1.10B | 16.49% |
| Dec 31, 2020 | 6.68B | 415.00M | 6.63% |
| Dec 31, 2019 | 6.26B | 435.00M | 7.47% |
| Dec 31, 2018 | 5.83B | 518.00M | 9.76% |
| Dec 31, 2017 | 5.31B | 419.00M | 8.57% |
| Dec 31, 2016 | 4.89B | 123.00M | 2.58% |
| Dec 31, 2015 | 4.77B | -20.00M | -0.42% |
| Dec 31, 2014 | 4.79B | 224.00M | 4.91% |
| Dec 31, 2013 | 4.56B | 225.00M | 5.19% |
| Dec 31, 2012 | 4.34B | 103.00M | 2.43% |
| Dec 31, 2011 | 4.23B | 651.00M | 18.17% |
| Dec 31, 2010 | 3.58B | 822.00M | 29.78% |
| Dec 31, 2009 | 2.76B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Takeda Pharmaceutical Company | 28.34B |
| Teva Pharmaceutical Industries | 17.35B |
| Haleon | 14.85B |
| Viatris | 14.56B |
| Elanco Animal Health | 4.89B |
| Dr. Reddy's Laboratories | 3.58B |
| United Therapeutics | 3.17B |
| Neurocrine Biosciences | 3.10B |
ZTS News
- 5 days ago - SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTS - PRNewsWire
- 6 days ago - Zoetis announces it recently launched Lenivia in Canada, EU - TheFly
- 6 days ago - Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union - Business Wire
- 7 days ago - Zoetis enters agreement to acquire VitalRADS, terms not disclosed - TheFly
- 7 days ago - Zoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic Capabilities - Business Wire
- 14 days ago - Zoetis granted EC Marketing Authorization for Poulvac Procerta vaccine - TheFly
- 14 days ago - Zoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND - Business Wire
- 15 days ago - Zoetis put volume heavy and directionally bearish - TheFly